| (Values in U.S. Thousands) | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 |
| Sales | 2,870 | 1,300 | 3,970 | 2,580 | 1,970 |
| Sales Growth | +120.77% | -67.25% | +53.88% | +30.96% | -83.57% |
| Net Income | -6,620 | -24,040 | -1,860 | -2,700 | -1,760 |
| Net Income Growth | +72.46% | -1,192.47% | +31.11% | -53.41% | -128.39% |
Kempharm Inc (KMPH)
5.81 -0.02 (-0.34%) 03/01/23 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime - - (-) -
for Tue, Feb 28th, 2023
KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States.